What is Retrogen?
Established in 1992, Retrogen has cemented its reputation as a cornerstone provider of genomic services. By leveraging decades of experience in high-throughput DNA sequencing, the company serves a diverse clientele spanning academic research institutions, industrial partners, and healthcare providers. Their comprehensive service portfolio includes next-generation sequencing, specialized molecular diagnostics, and critical testing solutions for infectious diseases and women's health. As a veteran player in the genomics sector, Retrogen maintains a rigorous commitment to quality and technical precision, ensuring that its diagnostic outputs meet the evolving demands of modern precision medicine and clinical research environments.
How much funding has Retrogen raised?
Retrogen has raised a total of $75K across 1 funding round:
Debt
$75K
Debt (2021): $75K with participation from PPP
Key Investors in Retrogen
PPP
Public-Private Partnership
What's next for Retrogen?
With the recent influx of capital, Retrogen is poised to transition into a more aggressive growth phase, likely focusing on the expansion of its clinical diagnostic infrastructure and the integration of advanced bioinformatics capabilities. The company's strategic roadmap suggests a move toward enhancing its market share in the high-growth molecular services sector. By optimizing its existing sequencing platforms and potentially diversifying its diagnostic offerings, Retrogen aims to solidify its competitive advantage. The current funding context suggests that the firm is moving beyond its foundational service model toward a more scalable, technology-driven enterprise, capable of addressing the increasing complexity of genomic data in global healthcare markets.
See full Retrogen company page
